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he treatment of schizophrenia represents one of the
most difficult areas of medicine for carrying out reliable
and informative clinical trials of new medicinal products.
The methodological issues that affect studies of neu-
roleptic agents are not unique.The evaluation of treat-
ments for negative symptoms probably represents the
most unusual methodological problem (not covered in
this paper),but from a statistical perspective this prob-
lem has parallels elsewhere in medicine.The real reason
why clinical trials in schizophrenia are so difficult is the
fact that a number of methodological issues are present
together and in a severe form.
This paper is concerned largely with trials that provide
the confirmatory evidence of the efficacy of new medic-
inal agents,that is those carried out during their phase 3
development or perhaps during the development of a
new indication in phase 4. Hence, it is concerned only
with controlled trials that provide the most reliable and
informative evidence of efficacy for licensing decisions.
General guidance on the statistical issues that arise in
confirmatory trials and that relate to regulatory decisions
can be found in ICH E9 (ICH,International Conference
on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use).
1
Guidance on the design,conduct,analysis,and interpre-
tation of these trials in the field of schizophrenia can be
found in the Committee for Proprietary Medicinal
Products (CPMP) Note for guidance.
2
Two issues require a broader introduction before dis-
cussing their impact on trials in schizophrenia.The first
is the use of placebo. The most recent revision of the
Declaration of Helsinki
3 in October 2000 caused alarm
among those conducting and carrying out controlled clin-
ical trials by appearing to limit the future role of placebo
to a serious extent.The use of placebo in schizophrenia
trials was already a problematic matter. Hence in the
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This paper discusses some methodological issues that are
relevant to the design of controlled trials of new medici-
nal products for use in the treatment of schizophrenia.
Two issues are covered more generally and at greater
length. The first is the use of placebo. Recent debate of
this topic was stimulated by changes to the Declaration of
Helsinki. The second is the design of studies to evaluate
maintenance treatment in the prevention of relapse and
recurrence. With respect to both of these issues, specific
implications for trials in schizophrenia are considered.
Additional design topics addressed briefly are noninferi-
ority designs, add-on designs, withdrawal designs, run-in
periods on placebo, loss to follow-up, and short-term and
long-term trials.
Dialogues Clin Neurosci. 2002;4:463-469.context of this paper,it is important to clarify the basis
of the concerns surrounding its use and to explain the
current resolution.
The second issue is the design of studies to evaluate the
long-term maintenance treatment of an episodic, or
partly episodic,condition.The use of medicinal products
for this purpose arises in a number of psychiatric and
other indications,and a terminology has been developed
to communicate thoughts and conclusions.The words
relapse,recurrence,and rebound all capture ideas that are
important for the underlying scientific model and for the
mechanism of action,but do they also capture ideas that
are critical to the use and licensing of medicinal products
and that must be individually assessed in clinical trials?
Following a general discussion of these two method-
ological issues,this paper will then relate the discussion
to the specific development of neuroleptics.A number of
other methodological issues highlighted by the CPMP
guideline will also be introduced at this point.
The use of placebo
In both Europe and the USA, the process of drafting
clinical guidelines for the development of new medicinal
products has often led to discussions concerning the
acceptability of the use of placebo in controlled trials.
There are those who take the view that it is unethical to
expose patients to placebo treatment when approved
medicinal products already exist for the condition in
question.
4There are others who stress the vital nature of
placebo-controlled clinical trials in establishing unequiv-
ocally the benefits of a new medication.At first sight,this
appears to be a conflict between the optimal treatment
of today’s patients and the optimal treatment of tomor-
row’s patients.The ethics of this well-known conflict are
a serious and difficult matter and one on which arbitra-
tion might reasonable be sought through the Declaration
of Helsinki (hereafter referred to as the Declaration).
Clinical trials sponsored by the pharmaceutical industry
generally defer to the Declaration on ethical matters and
a copy of it is attached to most protocols supported by
the industry.
The wording of earlier versions of the Declaration did
not provide much support for the use of placebo in con-
trolled trials in the situations where doubt arose.
However,there was uncertainty about its true interpre-
tation,and there was also a widely held view that it was
not intended to address the specific problems in question
in pharmaceutical development.These doubts were suf-
ficient to permit the use of placebo to continue relatively
unhindered by these specific ethical concerns.There was
hope that the revised version might clarify matters and
provide comfort to those who felt that they might be in
conflict with the wording, but not the spirit, of the
Declaration.However,section 29 of the revised version
contained the following text:
“The benefits, risks, burdens and effectiveness of a new
method should be tested against those of the best current
prophylactic, diagnostic and therapeutic methods.This
does not exclude the use of placebo, or no treatment,
where no proven prophylactic,diagnostic or therapeutic
method exists.”
This clearly did not change matters.It was an immediate
source of alarm to those responsible for the conduct and
approval of clinical trials,whether based in research insti-
tutes,medical practice,the pharmaceutical industry,or reg-
ulatory bodies.The resulting arguments have been cap-
tured in a number of publications and official statements.
5-11
Regulators in Europe and the USA all take the view that
there are a number of circumstances where a placebo arm
is acceptable and necessary in a controlled trial, even
when alternative proven (and licensed) therapies exist.
Firstly,it is argued that use of placebo is acceptable in the
following situations:
•The period on placebo (and therefore not on the
known effective agents) does not entail any additional
risk of serious or irreversible harm to the patient.
•The patient (or their legal representative) is capable of
giving,and gives,fully informed consent.
•The patient may request conventional treatment at any
stage,or may be placed on such treatment by the treat-
ing physician.
The key item in this list is clearly the first one because
the other items apply more generally to all clinical trial
procedures.If the line of argument advanced in the first
point is accepted,then it becomes important to have a
clear understanding of what constitutes serious or irre-
versible harm in each specific medical situation.
Secondly,it is argued that the use of placebo is scientifi-
cally necessary under those circumstances where active-
controlled trials are unreliable and where their use would
increase the proportion of erroneous clinical and regula-
tory decisions.This topic is thoroughly discussed in the
ICH E10 regulatory guideline on the choice of control.
12
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In some areas of medicine,the sensitivity of a specific trial
is an uncertain matter.For example,in the field of depres-
sion, there are plenty of examples of apparently good-
quality, placebo-controlled trials of established and
licensed agents that failed to detect a difference.
13 Such
trials are scientifically awkward and expensive,but clearly
cannot and do not form the basis of regulatory approvals;
they lead to delays and further research.However,in an
area of medicine where the paradoxical failure of a
placebo-controlled trial was a real possibility,a trial that
used a licensed treatment as the sole comparator arm
would also run the risk of failing to detect a real differ-
ence.That is,it might fail to pick up the inferiority of a test
agent to a standard agent.The lack of difference from the
standard agent could be equally paradoxical,but in this
case it could lead to a positive licensing decision.
Thirdly,some alternative (and regularly used) design strate-
gies using placebo avoid the apparent ethical dilemma,for
example,the addition of a new medication or placebo on
top of standard treatment (the “add-on”design).
Following widespread critical comment, the World
Medical Association (WMA) took the unusual step of
issuing a statement on their website that modifies the
position in the Declaration with respect to section 29.
3
This states that:
“… a placebo-controlled trial may be ethically acceptable,
even if proven therapy is available,under the following cir-
cumstances:
•Where for compelling and scientifically sound method-
ological reasons its use is necessary to determine the effi-
cacy or safety of a prophylactic,diagnostic or therapeu-
tic method,or
•Where a prophylactic,diagnostic or therapeutic method
is being investigated for a minor condition and the
patients who receive placebo will not be subject to any
additional risk of serious or irreversible harm.”
The new statement reflects a position that is close to the
regulatory viewpoint that just been expressed.The cur-
rent website wording does not quite cover all eventuali-
ties in a watertight manner, but there is a reasonable
chance that further negotiation could rectify this.Formal
adoption of the new wording,or similar wording,within
the Declaration requires ratification at the next meeting
of the WMA in October 2002. Assuming that this is
indeed the outcome,then a consensus on the continued
ethical use of placebo appears to have been reached.
Long-term studies of efficacy: 
relapse and recurrence
In various fields of medicine, there has been debate
about the precise meaning of the terms relapse and recur-
rence when applied to the response of patients to drug
treatment.Other terms such as rebound are often also
brought into the same discussion.Relapse and recurrence
both indicate a worsening of the patient’s symptoms.
Relapse indicates an increase in the patient’s symptoms
after successful treatment, but as part of the original
episode of disease.It must therefore occur within a rea-
sonably short time of treatment withdrawal.Recurrence,
on the other hand, is a reemergence of the patient’s
symptoms after a time without symptoms and is usually
regarded as the onset of a new episode of disease.
It is natural to wish to describe the effects of medicinal
products on the possibility of relapse and recurrence
because these are concepts in the treating physician’s
mind that help to communicate the benefits and risks of
treatment. Careful withdrawal of treatment may be
needed to prevent relapse. Continuation of treatment
may avoid relapse and prevent recurrence.However,in
practice,it can be difficult to reliably distinguish between
a relapse and a recurrence in an individual patient.It is
even more difficult to carry out clinical trials that can dis-
tinguish between the effect of a treatment on relapse and
its effect on recurrence.
Fortunately,for questions relating to the longer-term use
of treatments,this distinction does not greatly matter.The
key questions about length of treatment are usually
straightforward questions such as:
• For how long should I continue treatment?
• If I have successfully treated a patient for 6 months,is
further treatment clinically valuable?
There are designs of clinical trial that can answer these
questions without necessarily distinguishing between
effects on relapse and effects on recurrence.Although
this may lead to problems concerning the drafting of indi-
cations,it does not affect decisions concerning how to use
the treatment in the individual patient.
A design that would shed some light on the first question
above would be to randomize patients to,say,2 months
of active treatment followed by 4 months of placebo
(regimen A),4 months of active treatment followed by 2
months of placebo (regimen B), or 6 months of active
treatment (regimen C). The outcome might be reap-
pearance of positive symptoms in a suitably definedmanner.The superiority of the results on regimen B to
those on regimen A accompanied by the similarity of the
results on regimen B to those on regimen C would be an
indication that B was the best treatment regimen.
An alternative approach to answering the first question
would be to await a specific degree and duration of
response,and then randomize to continuing or stopping
treatment.
A design that would address the second question would
be one that took patients successfully treated for 6 months
and randomized them either to receive placebo or to con-
tinue active treatment for a further 3 months.Again the
outcome could be taken as the reappearance of positive
symptoms.The superiority of the active treatment arm
would indicate the value of continuing treatment.
To detect an effect on recurrence per se would require
the selection of patients who had been successfully
treated with the agent under investigation.The treatment
would then be stopped for a period of time in order to
establish that the first episode was over and that the pos-
sibility of relapse had gone.Patients who relapsed (had
positive symptoms) during this time would be withdrawn.
The remaining patients would then be randomized to
restarting active treatment or to placebo,and the reap-
pearance of positive symptoms would be assessed and
evaluated.Although a positive effect in such a study is
likely to indicate a real effect on recurrence,it is hard to
see that it would lead to the use of the treatment in a sim-
ilar manner in clinical practice. Hence the practical
importance of such a design must be doubtful,except as
an exploratory research tool.Phase 3 trials should reflect
the intended manner of use.
Specific issues for clinical trials in 
schizophrenia
Placebo-controlled, parallel-group comparisons
It should be clear from the discussion above that the sci-
entific need to use placebo as a comparator depends
upon whether trials against the currently licensed and
standard agents would reliably detect differences
between treatments if they existed. In practice, it also
depends upon confidence that standard treatments will
exhibit approximately the same size of effect in a new
trial as they did when they were originally tested against
placebo.This latter condition arises because it is neces-
sary to be able to judge what proportion of the benefit of
the comparator might be eroded by its replacement by
the treatment under test.Any “noninferiority”trial (trial
to show that the test treatment is no worse) against an
active comparator involves prespecifying a “noninferi-
ority margin”to define the degree of difference that is
clinically important and that it is necessary to exclude.
In schizophrenia,the main problem relating to the use of
active controls arises from lack of confidence that the size
of the treatment effect of a comparator agent could be reli-
ably predicted in a new trial setting.This is because there
have been changes and developments in many aspects of
the disease and its treatment that are critical to the size of
the observed benefits in clinical trials.There have been
changes to diagnostic criteria,efficacy criteria,the range
of available treatments, and the way in which they are
used.However,in addition to the problem of defining a
noninferiority margin, the different profile of effects of
newer agents on negative symptoms and extrapyramidal
side effects may confound direct comparisons of their
effects on positive symptoms.Furthermore,the large num-
ber of dropouts and noncompliers in schizophrenia trials
makes it harder to ensure the robustness of the conclu-
sions of a trial claiming to show the absence of a difference
between two agents,than it would be for a trial claiming
to show a difference from placebo.
Given that the historical basis for predicting the effect of
potential active comparators is shaky, it appears that
there is a scientific need to fall back on placebo-con-
trolled trials for straightforward head-to-head compar-
isons.But are they acceptable from an ethical perspec-
tive? Is there any danger of serious or irreversible harm?
This is a question for practicing clinicians to answer,but
it would seem likely that,at the very least,patients for
placebo-controlled trials would have to be selected with
considerable care.
Assuming that a placebo-controlled trial is possible,there
are strong reasons for including,in addition,a third arm
on a standard agent at an adequate dose.The third arm
provides an internal calibration of the efficacy results,
which is especially useful when the primary outcome is a
subjective rating scale. It also provides valuable infor-
mation about relative effects on positive and negative
symptoms.
Alternative designs
If there are ethical problems about the use of placebo,
then alternative designs must be considered.The add-on
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not satisfactorily controlled on standard therapy and ran-
domizing them to a test treatment in addition or to
placebo in addition.If this were successful,then a later
trial could take patients satisfactorily treated with the
combination of treatments (test plus standard) and ran-
domize them to continuing on the combination or the
test treatment alone.Patients randomized to test treat-
ment alone would have suitable rescue therapy available.
Data collected in this way would form a sound basis for
subsequent extension to broader first-line use of the test
agent through active-controlled trials.
Another possibility is to carry out a straightforward
placebo-controlled comparison,but to withdraw patients
from placebo or test treatment as soon as they exhibit
unacceptable symptoms.The time to withdrawal is then
a suitable outcome measure.Patients on placebo are only
exposed to risk for as long as they are acceptably treated
by placebo.
Run-in periods on placebo 
Initial washout periods are commonplace in trials of anti-
schizophrenic agents.This is for sound methodological
reasons related to properly characterizing the patients
and to ensuring that the effects of withdrawing any pre-
vious treatment do not contaminate the observed effects
of the test treatment. It is also common to treat all
patients with placebo during the run-in.
The case against using placebo during the run-in has
been argued strongly by Senn.
14,15 He points out that this
stratagem involves the treating physician deceiving the
patient,whereas in more conventional uses of placebo
both are in the same state of ignorance.As far as the sub-
sequent comparison of randomized treatment arms is
concerned,it would be just as acceptable to have a run-
in without treatment:it does no harm to the main objec-
tive of the study. The onus to prove their case lies
squarely on those who believe that placebo treatment is
necessary during a run-in.
Losses of patients from clinical trials
The incidence of dropout from clinical trials in schizo-
phrenia is high.This is one of the factors that make these
trials particularly difficult to interpret because the biases
introduced by dropouts are difficult to assess.All possi-
ble steps should be taken to minimize the number of
dropouts and to shed light on the potential bias they
induce.The reasons for dropout should be carefully doc-
umented.After stopping their trial medication,dropouts
should still be followed up as fully as possible as planned
in the protocol.Key measurements should also be made
at the time of stopping treatment.
The primary analysis of a placebo-controlled comparison
should include all randomized patients regardless of
dropout.A “per protocol” analysis should support the
primary analysis.There should be a full exploration of the
sensitivity of the main results of the trial to the influence
of the dropouts, taking into account the reasons for
dropout and the corresponding potential biases that they
might cause.
Short-term trials
The efficacy of a neuroleptic agent can generally be
established in a short-term trial lasting about 6 weeks,
studying acute exacerbations of the disease.A dose-rang-
ing study might include three or more doses, placebo
(ethically justified,as described earlier),and a standard
treatment arm, making five treatment arms in all, to
establish the optimal dose and the lower end of the dose
range.A phase 3 confirmatory study would use the dos-
ing regimen intended for licensing and would also ideally
include placebo and active control.
Long-term studies
The difficulties inherent in schizophrenia trials make it
imperative that licensing decisions are made on the basis
of controlled trial data.It is not sufficient to monitor a
group of patients exposed to long-term therapy and
record their progress.The data from such a study would
probably be supportive,especially for safety purposes,
but would not establish a regulatory claim.The duration
of controlled data adequate to establish use as mainte-
nance therapy is of the order of 1 year.It is difficult to
envisage ethical use of placebo over this timescale and so
active control seems inevitable.If a straightforward ran-
domized comparison over a period of 1 year is under-
taken,then it will be necessary to defend the sensitivity
of the trial,that is,its ability to detect clinically important
differences from the active control,if they exist.This will
probably have to take into account a high level of
dropout and noncompliance,and that could clearly pose
problems.
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make use of the designs described earlier in the section
Long-term studies of efficacy:relapse and recurrence.This
might be done sequentially,first establishing that 3 or 6
months’ treatment was better than treatment that stopped
after the acute exacerbation,and then going on to 1 year.
Patients whose acute episode was successfully treated by
the test treatment could be randomized to placebo (stop-
ping treatment) or test treatment.Those who survived
successfully on test until 6 months,say,could then be ran-
domized again to placebo or to test treatment.In this way,
the value of continuing treatment at each selected time
point would be established. The problem of dropouts
would be reduced because only those who reached each
time point would be rerandomized.
In trials of this nature,a natural primary outcome mea-
sure would be the time to the reappearance of positive
symptoms,suitably defined.A “time to event”analysis of
this outcome would be appropriate.In this analysis,no
distinction need be made between relapse and recur-
rence in the primary analysis,although secondary analy-
ses might consider this distinction.Other measurements
of symptoms and adverse effects could also be used to
support the primary outcome.
A positive conclusion of a trial using this type of design
implies that continued treatment up to and beyond the
point of randomization is worthwhile. Hence the later
that randomization is deferred,the longer the treatment
period that can be supported by the trial.However,the
later that randomization is deferred,the more patients
will leave the trial before randomization,and so the more
must be entered at the start.In addition,after random-
ization the trial must continue for a reasonably long
period of time in order to collect sufficient “events.”
There are likely to be limits on the numbers of patients
that can be recruited initially and on the overall length
of the trial that will place practical restrictions on this
design. ❏
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Diseños y duración de estudios y elección de
fármacos de comparación incluyendo el
empleo de placebo
Este artículo discute algunos aspectos metodológicos
que son relevantes para el diseño de ensayos contro-
lados de nuevos productos medicinales para ser uti-
lizados en el tratamiento de la esquizofrenia. En
forma más general y en mayor extensión se abordan
dos aspectos. El primero es el empleo de placebo.
Cambios en la Declaración de Helsinki estimularon un
reciente debate acerca de este tópico. El segundo
aspecto es el diseño de estudios para evaluar el tra-
tamiento de mantención en la prevención de recaídas
y recurrencias. Se han considerado las implicancias
específicas que tienen ambos aspectos para los ensa-
yos en esquizofrenia. Otros temas de diseño, mencio-
nados brevemente, son diseños de “no inferioridad,”
diseños de tratamientos combinados, diseños de eva-
luación de abandono de tratamiento, estudios con
fare de preinclusión con placebo, con pérdidas del
seguimiento y estudios a corto y a largo plazo. 
Schémas d’études, durée des études et choix
des comparateurs y compris d’un placebo
Cet article passe en revue quelques points de métho-
dologie concernant les schémas d’études contrôlées
portant sur les nouveaux médicaments utilisés dans
le traitement de la schizophrénie. Deux points sont
traités de façon plus générale et plus longuement.
Le premier concerne l’utilisation d’un placebo ainsi
que le récent débat sur ce sujet suscité par les modi-
fications apportées à la Déclaration d’Helsinki. Le
second se rapporte aux schémas d’études destinées
à évaluer le traitement d’entretien pour prévenir les
rechutes ou les récurrences. Les aspects spécifiques
de ces deux points vis-à-vis de la schizophrénie sont
détaillés, avant d’aborder plus rapidement d’autres
aspects méthodologiques tels que les schémas de «
non-infériorité », les schémas de traitement associé,
les schémas avec sorties d’étude, les études avec
phase de préinclusion sous placebo, avec perdus de
vue et les essais à court et à long terme.Study design and duration in schizophrenia - Lewis  Dialogues in Clinical Neuroscience - Vol 4 . No.4 . 2002
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